Genentech
Private Company
Funding information not available
Overview
Genentech is a foundational and highly successful biotechnology company that pioneered the industry with its early work in genetic engineering and antibody therapeutics. As a wholly-owned subsidiary of Roche since 2009, it operates with significant autonomy, serving as the U.S. pharmaceutical headquarters and maintaining its distinct 'startup' culture in research and early development. The company has a storied history of delivering transformative medicines, particularly in oncology and neurology, and continues to focus on bold science, inclusive research practices, and addressing unmet medical needs.
Technology Platform
Pioneer and leader in recombinant DNA technology, with deep expertise in antibody engineering, biologics development, and small molecule discovery. Integrates genetics, molecular biology, and translational medicine for a 'bench-to-bedside' approach.
Opportunities
Risk Factors
Competitive Landscape
Genentech competes in the upper echelon of the global biopharmaceutical industry, facing off against other major players like Pfizer, Merck, Novartis, and Amgen, as well as innovative biotechnology companies. Its competitive advantage lies in its historic scientific prowess, strong culture of innovation, and the unparalleled resources and stability provided by its parent company, Roche, allowing it to compete effectively across discovery, development, and commercialization.